FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1526279464> ?p ?o ?g. }

• W1526279464 endingPage "295" @default.
• W1526279464 startingPage "284" @default.
• W1526279464 abstract "WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • The marked between variability in the rate of progression of Parkinson's disease severity assessed with a global functional score (Unified Parkinson' Disease Rating Scale, UPDRS) is recognized but its origin is uncertain and variously attributed to different subtypes of Parkinson's disease, life style, genetic variability and treatment. An increased risk of death in patients treated with selegiline has been reported but this is controversial. WHAT THIS STUDY ADDS • We used a hazard model approach to describe the time to clinical events (death, disability, depression and dementia). The time course of disease status changes was shown to be a key predictor of the risk of these events. Baseline motor subtype was not a predictor of outcome events. Selegiline was associated with an increased risk of death that was independent of its effect on disease status. AIM To describe the time to clinical events (death, disability, cognitive impairment and depression) in Parkinson's disease using the time course of disease status and treatment as explanatory variables. METHODS Disease status based on the Unified Parkinson's Disease Rating Scale (UPDRS) and the time to clinical outcome events were obtained from 800 patients who initially had early Parkinson's disease. Parametric hazard models were used to describe the time to the events of interest. RESULTS Time course of disease status (severity) was an important predictor of clinical outcome events. There was an increased hazard ratio for death 1.4 (95% CI 1.31, 149), disability 2.75 (95% CI 2.30, 3.28), cognitive impairment 4.35 (95% CI 1.94, 9.74), and depressive state 1.43 (95% CI 1.26, 1.63) with each 10 unit increase of UPDRS. Age at study entry increased the hazard with hazard ratios of 49.1 (95% CI 8.7, 278) for death, 4.76 (95% CI 1.10, 20.6) for disability and 90.0 (95% CI 63.3–128) for cognitive impairment at age 60 years. Selegiline treatment had independent effects as a predictor of death at 8 year follow‐up with a hazard ratio of 2.54 (95% CI 1.51, 4.25) but had beneficial effects on disability with a hazard ratio of 0.363 (95% CI 0.132, 0.533) and depression with a hazard ratio of 0.372 (95% CI 0.12, 0.552). CONCLUSIONS Our findings show that the time course of disease status based on UPDRS is a much better predictor of future clinical events than any baseline disease characteristic. Continued selegiline treatment appears to increase the hazard of death." @default.
• W1526279464 created "2016-06-24" @default.
• W1526279464 creator A5037048137 @default.
• W1526279464 creator A5037361988 @default.
• W1526279464 creator A5087796927 @default.
• W1526279464 date "2012-07-10" @default.
• W1526279464 modified "2023-10-17" @default.
• W1526279464 title "Disease progress and response to treatment as predictors of survival, disability, cognitive impairment and depression in Parkinson's disease" @default.
• W1526279464 cites W131857772 @default.
• W1526279464 cites W1486637732 @default.
• W1526279464 cites W1516230268 @default.
• W1526279464 cites W1586118024 @default.
• W1526279464 cites W1663526792 @default.
• W1526279464 cites W1847168837 @default.
• W1526279464 cites W1929069690 @default.
• W1526279464 cites W1976536148 @default.
• W1526279464 cites W1979130463 @default.
• W1526279464 cites W1985419794 @default.
• W1526279464 cites W1989070599 @default.
• W1526279464 cites W1989153256 @default.
• W1526279464 cites W1989703263 @default.
• W1526279464 cites W1990627055 @default.
• W1526279464 cites W2000016536 @default.
• W1526279464 cites W2001496329 @default.
• W1526279464 cites W2022207083 @default.
• W1526279464 cites W2033803586 @default.
• W1526279464 cites W2042965414 @default.
• W1526279464 cites W2048957687 @default.
• W1526279464 cites W2055244664 @default.
• W1526279464 cites W2058007888 @default.
• W1526279464 cites W2062309915 @default.
• W1526279464 cites W2063956606 @default.
• W1526279464 cites W2067726982 @default.
• W1526279464 cites W2070500117 @default.
• W1526279464 cites W2098815078 @default.
• W1526279464 cites W2103304172 @default.
• W1526279464 cites W2109140840 @default.
• W1526279464 cites W2120672570 @default.
• W1526279464 cites W2127670282 @default.
• W1526279464 cites W2137669059 @default.
• W1526279464 cites W2141495158 @default.
• W1526279464 cites W2160070901 @default.
• W1526279464 cites W2166609052 @default.
• W1526279464 cites W2170202134 @default.
• W1526279464 cites W2614720968 @default.
• W1526279464 cites W4232719749 @default.
• W1526279464 doi "https://doi.org/10.1111/j.1365-2125.2012.04208.x" @default.
• W1526279464 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3630748" @default.
• W1526279464 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22300470" @default.
• W1526279464 hasPublicationYear "2012" @default.
• W1526279464 type Work @default.
• W1526279464 sameAs 1526279464 @default.
• W1526279464 citedByCount "40" @default.
• W1526279464 countsByYear W15262794642012 @default.
• W1526279464 countsByYear W15262794642013 @default.
• W1526279464 countsByYear W15262794642014 @default.
• W1526279464 countsByYear W15262794642015 @default.
• W1526279464 countsByYear W15262794642016 @default.
• W1526279464 countsByYear W15262794642017 @default.
• W1526279464 countsByYear W15262794642018 @default.
• W1526279464 countsByYear W15262794642019 @default.
• W1526279464 countsByYear W15262794642020 @default.
• W1526279464 countsByYear W15262794642021 @default.
• W1526279464 countsByYear W15262794642022 @default.
• W1526279464 countsByYear W15262794642023 @default.
• W1526279464 crossrefType "journal-article" @default.
• W1526279464 hasAuthorship W1526279464A5037048137 @default.
• W1526279464 hasAuthorship W1526279464A5037361988 @default.
• W1526279464 hasAuthorship W1526279464A5087796927 @default.
• W1526279464 hasBestOaLocation W15262794642 @default.
• W1526279464 hasConcept C118552586 @default.
• W1526279464 hasConcept C126322002 @default.
• W1526279464 hasConcept C138496976 @default.
• W1526279464 hasConcept C139719470 @default.
• W1526279464 hasConcept C15744967 @default.
• W1526279464 hasConcept C162324750 @default.
• W1526279464 hasConcept C1862650 @default.
• W1526279464 hasConcept C207103383 @default.
• W1526279464 hasConcept C2776134090 @default.
• W1526279464 hasConcept C2776867660 @default.
• W1526279464 hasConcept C2779134260 @default.
• W1526279464 hasConcept C2779483572 @default.
• W1526279464 hasConcept C2779734285 @default.
• W1526279464 hasConcept C44249647 @default.
• W1526279464 hasConcept C50382708 @default.
• W1526279464 hasConcept C71924100 @default.
• W1526279464 hasConcept C83849319 @default.
• W1526279464 hasConceptScore W1526279464C118552586 @default.
• W1526279464 hasConceptScore W1526279464C126322002 @default.
• W1526279464 hasConceptScore W1526279464C138496976 @default.
• W1526279464 hasConceptScore W1526279464C139719470 @default.
• W1526279464 hasConceptScore W1526279464C15744967 @default.
• W1526279464 hasConceptScore W1526279464C162324750 @default.
• W1526279464 hasConceptScore W1526279464C1862650 @default.
• W1526279464 hasConceptScore W1526279464C207103383 @default.
• W1526279464 hasConceptScore W1526279464C2776134090 @default.
• W1526279464 hasConceptScore W1526279464C2776867660 @default.
• W1526279464 hasConceptScore W1526279464C2779134260 @default.

• next